…
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Concord Medical Services Holdings operates a network of oncology-focused clinics and hospital departments across China, providing radiotherapy, nuclear medicine and diagnostic services. Long-term growth may be supported by demographic trends and rising cancer incidence, under-penetration of advanced radiotherapy in many regions, and expansion of outpatient and diagnostic capacity. Investors may find the company attractive for its specialist focus, scale advantages in equipment and staff deployment, and a revenue base linked to recurring patient treatments.
Key investment risks include regulatory and reimbursement changes in China's healthcare system, strong competition from public hospitals and other private chains, capital intensity and execution risk associated with opening and operating treatment facilities.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -669.58M | -555.59M | -839.90M | -441.65M | -441.65M |
| Minority interest | 343.83M | 233.36M | 279.33M | 251.25M | 3063.78M |
| Net income | -308.24M | -297.66M | -768.99M | -404.03M | -404.03M |
| Selling general administrative | 404.37M | 330.08M | 311.16M | 294.82M | 294.82M |
| Selling and marketing expenses | 48.63M | 56.30M | 61.48M | 25.76M | 25.76M |
| Gross profit | -79.16M | -76.61M | -152.41M | 13.08M | 13.08M |
| Reconciled depreciation | 130.76M | 128.45M | 132.81M | 104.08M | 80.30M |
| Ebit | -476.38M | -462.99M | -525.05M | -307.50M | -307.50M |
| Ebitda | -345.62M | -344.16M | -581.17M | -206.43M | -206.43M |
| Depreciation and amortization | 130.76M | 118.83M | -56.12M | 101.07M | 101.07M |
| Operating income | -532.16M | -462.99M | -525.05M | -307.50M | -307.50M |
| Other operating expenses | 916.12M | 1000.39M | 997.13M | 530.51M | 530.51M |
| Interest expense | 193.20M | 165.67M | 120.36M | 81.36M | 81.36M |
| Tax provision | -17.50M | -24.57M | -70.91M | -6.57M | -37.62M |
| Interest income | 13.98M | 10.83M | 10.02M | 5.89M | 8.44M |
| Net interest income | -179.22M | -154.84M | -110.34M | -67.89M | -72.92M |
| Income tax expense | -17.50M | -24.57M | -70.91M | -37.62M | -37.62M |
| Total revenue | 383.96M | 537.40M | 472.08M | 223.01M | 223.01M |
| Total operating expenses | 453.00M | 386.38M | 372.64M | 320.58M | 320.58M |
| Cost of revenue | 463.12M | 614.01M | 624.49M | 209.93M | 209.93M |
| Total other income expense net | -137.42M | -92.61M | -314.85M | -134.15M | -134.15M |
| Net income from continuing ops | -652.08M | -531.02M | -768.99M | -522.67M | -404.03M |
| Net income applicable to common shares | -308.24M | -297.66M | -489.66M | -820.62M | -669.91M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 6726.39M | 6053.94M | 6004.93M | 5334.54M | 5334.54M |
| Intangible assets | 680.37M | 323.29M | 762.09M | 522.82M | 522.82M |
| Other current assets | 548.52M | 445.23M | 24.27M | 31.41M | 31.41M |
| Total liab | 5108.64M | 4306.96M | 3989.28M | 2933.71M | 2933.71M |
| Total stockholder equity | -2280.39M | -2121.95M | -1863.97M | -662.96M | -662.96M |
| Other current liab | 767.34M | 716.34M | 325.19M | 243.21M | 243.21M |
| Common stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Capital stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Retained earnings | -4372.83M | -4064.59M | -3766.93M | -2456.65M | -2456.65M |
| Other liab | - | - | - | 268.89M | 230.06M |
| Good will | 572.22M | 575.43M | 575.43M | 213.66M | 213.66M |
| Other assets | 180.75M | - | 24.02M | 250.58M | 409.88M |
| Cash | 216.22M | 58.14M | 158.28M | 334.26M | 334.26M |
| Cash and equivalents | 216.22M | - | - | 157.39M | 334.26M |
| Total current liabilities | 2125.36M | 1951.39M | 1121.24M | 512.12M | 512.12M |
| Current deferred revenue | 46.15M | 59.41M | 100.80M | 87.74M | 87.74M |
| Net debt | 3714.51M | 3237.56M | 3081.60M | 2019.80M | 2019.80M |
| Short term debt | 1078.14M | 1088.68M | 548.50M | 162.54M | 162.54M |
| Short long term debt | 1032.70M | 1042.19M | 512.58M | 299.35M | 148.88M |
| Short long term debt total | 3930.73M | 3295.70M | 3239.88M | 2354.06M | 2354.06M |
| Other stockholder equity | 2169.69M | 2007.96M | 1930.63M | 1840.02M | 1840.02M |
| Property plant equipment | 4225.14M | - | 3854.04M | 3764.56M | 3199.16M |
| Total current assets | 983.97M | 617.21M | 759.80M | 676.00M | 676.00M |
| Long term investments | 472.17M | 394.71M | 437.87M | 390.62M | 313.02M |
| Net tangible assets | - | - | -2793.16M | -2609.83M | -1399.43M |
| Short term investments | 134.62M | - | - | 2.70M | 25.05M |
| Net receivables | 51.17M | 73.50M | 512.82M | 280.39M | 280.39M |
| Long term debt | 2713.69M | 2014.01M | 2491.43M | 2198.60M | 1968.05M |
| Inventory | 33.44M | 40.35M | 84.83M | 21.61M | 21.61M |
| Accounts payable | 199.39M | 129.24M | 146.75M | 18.63M | 18.63M |
| Accumulated other comprehensive income | -77.35M | -65.42M | -27.77M | -46.43M | -46.43M |
| Treasury stock | - | - | - | - | -0.01M |
| Non currrent assets other | 5.87M | 16.07M | 23.19M | 107.47M | 107.47M |
| Non current assets total | 5742.42M | 5436.73M | 5245.13M | 4658.54M | 4658.54M |
| Capital lease obligations | 184.34M | 239.50M | 235.87M | 234.71M | 237.14M |
| Long term debt total | 2693.69M | - | - | 2178.60M | 1968.05M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -593.44M | -47.68M | -118.79M | -565.98M | -239.31M |
| Change to liabilities | - | - | 170.91M | 69.38M | 95.66M |
| Total cashflows from investing activities | -593.44M | -47.68M | -118.79M | -565.98M | -533.88M |
| Net borrowings | 970.87M | 19.43M | 383.09M | 245.53M | 353.10M |
| Total cash from financing activities | 1146.03M | 257.65M | 383.09M | 1138.30M | 1138.30M |
| Change to operating activities | - | - | -14.05M | -46.94M | -79.76M |
| Net income | -652.08M | -297.66M | -768.99M | -404.03M | -404.03M |
| Change in cash | 146.56M | -68.92M | 0.43M | 372.09M | 372.09M |
| Begin period cash flow | 90.42M | 159.34M | 158.91M | 74.31M | 74.31M |
| End period cash flow | 236.98M | 90.42M | 159.34M | 446.39M | 446.39M |
| Total cash from operating activities | -397.75M | -276.47M | -216.69M | -229.77M | -229.77M |
| Issuance of capital stock | 510.52M | 0.00M | - | - | - |
| Depreciation | 130.76M | 128.45M | 132.81M | 80.30M | 80.30M |
| Other cashflows from investing activities | -0.16M | 68.02M | 237.88M | -267.29M | -7.17M |
| Change to inventory | 6.50M | 44.49M | -46.75M | -14.45M | -14.45M |
| Change to account receivables | 12.02M | 36.45M | 0.64M | -6.17M | -6.17M |
| Sale purchase of stock | 510.52M | - | - | - | - |
| Other cashflows from financing activities | -335.36M | 194.84M | 777.69M | 2409.30M | 2409.30M |
| Change to netincome | - | - | 35.12M | -145.37M | 32.54M |
| Capital expenditures | 410.83M | 115.70M | 384.81M | 512.90M | 512.90M |
| Change in working capital | -149.33M | -14.49M | 105.03M | -32.62M | -32.62M |
| Stock based compensation | 0.00M | 0.00M | -5.92M | 20.62M | 20.62M |
| Other non cash items | 288.55M | -92.78M | 392.22M | 119.31M | 119.31M |
| Free cash flow | -808.58M | -392.17M | -601.50M | -742.67M | -742.67M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CCM Concord Medical Services Holdings |
0.02 0.54% |
3.73 | - | - | 0.05 | 3.00 | 10.28 | -0.96 |
| HCA HCA Healthcare, Inc. |
- -% |
504.89 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
5.67 2.00% |
289.00 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.34 2.34% |
14.86 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
0.29 5.59% |
5.57 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jianyu Yang | Chairman & CEO | 1971 |
| Mr. Boxun Zhang | Chief Financial Officer | 1976 |
| Ms. Xun Liu | Financial Controller | NA |
| Mr. Wei Jiang | Chief Financial Officer | 1980 |
| Mr. Boxun Zhang | Chief Strategy Officer | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.